Cargando…

PARP inhibitor re-sensitizes Adriamycin resistant leukemia cells through DNA damage and apoptosis

Resistance to Adriamycin (ADR) is an increasing problem in the treatment of leukemia and the development of novel therapeutic strategies is becoming increasingly important. Olaparib is a poly (adenosine diphosphate-ribose) polymerase (PARP) 1 inhibitor, which has promising antitumor activity in pati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Jie, Xiao, Sheng, Yuan, Miaomiao, Li, Qianyuan, Xiao, Guangfen, Wu, Wei, Ouyang, Yuexian, Huang, Lihua, Yao, Chenjiao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2019
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6297734/ https://www.ncbi.nlm.nih.gov/pubmed/30431088 http://dx.doi.org/10.3892/mmr.2018.9628

Ejemplares similares

Inhibiting 4E-BP1 re-activation represses podocyte cell cycle re-entry and apoptosis induced by adriamycin
por: Li, Fang, et al.
Publicado: (2019)

Identification and validation of an immunological microenvironment signature and prediction model for epstein-barr virus positive lymphoma: Implications for immunotherapy
por: Yao, Chenjiao, et al.
Publicado: (2022)

IKKα inhibition re-sensitizes acquired adriamycin-resistant triple negative breast cancer cells to chemotherapy-induced apoptosis
por: Liao, Jian, et al.
Publicado: (2023)

NBDHEX re‐sensitizes adriamycin‐resistant breast cancer by inhibiting glutathione S‐transferase pi
por: Sha, Huanhuan, et al.
Publicado: (2022)

RNA interference-mediated FANCF silencing sensitizes OVCAR3 ovarian cancer cells to adriamycin through increased adriamycin-induced apoptosis dependent on JNK activation
por: HE, MIAO, et al.
Publicado: (2013)

RNA interference-mediated FANCF silencing sensitizes OVCAR3 ovarian cancer cells to adriamycin through increased adriamycin-induced apoptosis dependent on JNK activation
por: He, Miao, et al.
Publicado: (2022)

PARP1-Driven Apoptosis in Chronic Lymphocytic Leukemia
por: Diamantopoulos, Panagiotis T., et al.
Publicado: (2014)

Naringenin suppresses K562 human leukemia cell proliferation and ameliorates Adriamycin-induced oxidative damage in polymorphonuclear leukocytes
por: LI, RUI-FANG, et al.
Publicado: (2015)

Adriamycin does not damage podocytes of zebrafish larvae
por: Schindler, Maximilian, et al.
Publicado: (2020)

Sensitization of cervix cancer cells to Adriamycin by Pentoxifylline induces an increase in apoptosis and decrease senescence
por: Bravo-Cuellar, Alejandro, et al.
Publicado: (2010)

Adriamycin-resistant cells are significantly less fit than adriamycin-sensitive cells in cervical cancer
por: Qi, Min, et al.
Publicado: (2021)

WYE-354 restores Adriamycin sensitivity in multidrug-resistant acute myeloid leukemia cell lines
por: Ibrahim, Sara M., et al.
Publicado: (2019)

Downregulated miR-130a enhances the sensitivity of acute myeloid leukemia cells to Adriamycin
por: Liu, Huimin, et al.
Publicado: (2020)

Ophiobolin-O Reverses Adriamycin Resistance via Cell Cycle Arrest and Apoptosis Sensitization in Adriamycin-Resistant Human Breast Carcinoma (MCF-7/ADR) Cells
por: Sun, Wenxia, et al.
Publicado: (2013)

LncRNA H19 Regulates Breast Cancer DNA Damage Response and Sensitivity to PARP Inhibitors via Binding to ILF2
por: Zhao, Junsong, et al.
Publicado: (2023)

Apoptosis and remodeling in adriamycin-induced cardiomyopathy rat model
por: Hong, Young Mi, et al.
Publicado: (2017)

Artesunate enhances adriamycin cytotoxicity by inhibiting glycolysis in adriamycin-resistant chronic myeloid leukemia K562/ADR cells
por: Chen, Li, et al.
Publicado: (2019)

The advanced lung cancer inflammation index predicts chemotherapy response and infection risk in multiple myeloma patients receiving induction chemotherapy
por: Cheng, Jie, et al.
Publicado: (2022)

PARP inhibitors trap PARP2 and alter the mode of recruitment of PARP2 at DNA damage sites
por: Lin, Xiaohui, et al.
Publicado: (2022)

Inhibitors of adriamycin-induced histamine release in vitro limit adriamycin cardiotoxicity in vivo.
por: Klugmann, F. B., et al.
Publicado: (1986)

Germacrone reverses Adriamycin resistance through cell apoptosis in multidrug-resistant breast cancer cells
por: XIE, XIAO-HONG, et al.
Publicado: (2014)

TUG1 knockdown enhances adriamycin cytotoxicity by inhibiting glycolysis in adriamycin-resistant acute myeloid leukemia HL60/ADR cells
por: Chen, Li, et al.
Publicado: (2019)

Protection Effect of Zhen-Wu-Tang on Adriamycin-Induced Nephrotic Syndrome via Inhibiting Oxidative Lesions and Inflammation Damage
por: Liang, Chun-ling, et al.
Publicado: (2014)

Interaction between ATM and PARP-1 in response to DNA damage and sensitization of ATM deficient cells through PARP inhibition
por: Aguilar-Quesada, Rocío, et al.
Publicado: (2007)

Adriamycin/cyclophosphamide and adriamycin/melphalan in advanced L1210 leukaemia.
por: Tobias, J. S., et al.
Publicado: (1975)

Predicting PARP inhibitor sensitivity and resistance
por: Bebb, D. Gwyn, et al.
Publicado: (2012)

USP37 downregulation elevates the Chemical Sensitivity of Human Breast Cancer Cells to Adriamycin
por: Qin, Tao, et al.
Publicado: (2021)

Therapeutic Potential of Astragaloside IV Against Adriamycin-Induced Renal Damage in Rats via Ferroptosis
por: Qin, Lu-Yun, et al.
Publicado: (2022)

PARP-1 inhibitors enhance the chemosensitivity of leukemia cells by attenuating NF- кB pathway activity and DNA damage response induced by Idarubicin : PARP-1 inhibitors attenuate DNA damage response
por: Ke, Bo, et al.
Publicado: (2021)

LKB1 is a DNA damage response protein that regulates cellular sensitivity to PARP inhibitors
por: Wang, Yi-Shu, et al.
Publicado: (2016)

Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies
por: Padella, Antonella, et al.
Publicado: (2022)

Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing’s Sarcoma
por: Gill, Sonja J., et al.
Publicado: (2015)

Astragalus Polysaccharide Promotes Adriamycin-Induced Apoptosis in Gastric Cancer Cells
por: Song, Jie, et al.
Publicado: (2020)

Losartan Reduces Remodeling and Apoptosis in an Adriamycin-Induced Cardiomyopathy Rat Model
por: Kim, Hyeon A, et al.
Publicado: (2023)

Givinostat, a type II histone deacetylase inhibitor, induces potent caspase-dependent apoptosis in human lymphoblastic leukemia
por: Li, Ying, et al.
Publicado: (2016)

Silencing of CHFR Sensitizes Gastric Carcinoma to PARP Inhibitor Treatment
por: Li, Yuan, et al.
Publicado: (2019)

PARP Power: A Structural Perspective on PARP1, PARP2, and PARP3 in DNA Damage Repair and Nucleosome Remodelling
por: van Beek, Lotte, et al.
Publicado: (2021)

Clinical PARP inhibitors do not abrogate PARP1 exchange at DNA damage sites in vivo
por: Shao, Zhengping, et al.
Publicado: (2020)

Glomerular Endothelial Cell Injury and Damage Precedes That of Podocytes in Adriamycin-Induced Nephropathy
por: Sun, Yu Bo Yang, et al.
Publicado: (2013)

Sensitizing thermochemotherapy with a PARP1-inhibitor
por: Oei, Arlene L, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_81geevg5ufnkcqfhcnemklrmn5